In the past week, WVE stock has gone up by 8.17%, with a monthly gain of 76.34% and a quarterly surge of 174.12%. The volatility ratio for the week is 5.42%, and the volatility levels for the last 30 days are 6.84% for Wave Life Sciences Ltd The simple moving average for the last 20 days is 8.68% for WVE’s stock, with a simple moving average of 126.78% for the last 200 days.
Is It Worth Investing in Wave Life Sciences Ltd (NASDAQ: WVE) Right Now?
WVE has 36-month beta value of -1.24. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WVE is 120.28M, and currently, short sellers hold a 4.07% ratio of that float. The average trading volume of WVE on November 08, 2024 was 1.66M shares.
WVE) stock’s latest price update
Wave Life Sciences Ltd (NASDAQ: WVE)’s stock price has gone rise by 4.44 in comparison to its previous close of 14.20, however, the company has experienced a 8.17% increase in its stock price over the last five trading days. zacks.com reported 2024-11-05 that Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Raymond James repeating the rating for WVE by listing it as a “Strong Buy.” The predicted price for WVE in the upcoming period, according to Raymond James is $22 based on the research report published on October 16, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see WVE reach a price target of $13, previously predicting the price at $10. The rating they have provided for WVE stocks is “Overweight” according to the report published on September 27th, 2024.
B. Riley Securities gave a rating of “Buy” to WVE, setting the target price at $11 in the report published on September 19th of the current year.
WVE Trading at 55.28% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.85% of loss for the given period.
Volatility was left at 6.84%, however, over the last 30 days, the volatility rate increased by 5.42%, as shares surge +79.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +165.30% upper at present.
During the last 5 trading sessions, WVE rose by +8.17%, which changed the moving average for the period of 200-days by +237.05% in comparison to the 20-day moving average, which settled at $13.65. In addition, Wave Life Sciences Ltd saw 193.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from Francis Chris, who sale 208,836 shares at the price of $13.67 back on Oct 16 ’24. After this action, Francis Chris now owns 0 shares of Wave Life Sciences Ltd, valued at $2,855,051 using the latest closing price.
BOLNO PAUL, the President and CEO of Wave Life Sciences Ltd, sale 90,474 shares at $15.00 during a trade that took place back on Oct 16 ’24, which means that BOLNO PAUL is holding 268,585 shares at $1,357,110 based on the most recent closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.92 for the gross margin
The net margin for Wave Life Sciences Ltd stands at -0.67. The total capital return value is set at -2.34. Equity return is now at value -1928.16, with -33.61 for asset returns.
Based on Wave Life Sciences Ltd (WVE), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -4.44. The debt to equity ratio resting at 6.57. The interest coverage ratio of the stock is -29.06.
Currently, EBITDA for the company is -58.79 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of 19.66. The receivables turnover for the company is 85.66for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
To put it simply, Wave Life Sciences Ltd (WVE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
